PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN GRANGEMOUTH, SCOTLAND
18 Dec 2023
ADC
Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approximately 70-80%
Adrian Gillespie, Chief Executive of Scottish Enterprise, joins senior Piramal management team and site leadership to mark the occasion
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
MUMBAI, India and GRANGEMOUTH, Scotland, Dec. 18, 2023 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) (NSE: PPLPHARMA) (BSE: 543635), today celebrated the opening of its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.
Continue Reading
Preview
Source: PRNewswire
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions
Preview
Source: PRNewswire
Adrian Gillespie, Chief Executive of Scottish Enterprise
Preview
Source: PRNewswire
Wellbeing Economy Secretary Neil Gray
Preview
Source: PRNewswire
Ceremonial Ribbon Cutting, Piramal Pharma Solutions Grangemouth, Scotland Site Expansion. Left to right: Adrian Gillespie, Chief Executive of Scottish Enterprise; Herve Berdou, COO, Piramal Pharma Solutions; Francois Houbart, Managing Director and Grangemouth Site Head, Piramal Pharma Solutions; Nandini Piramal, Chairperson, Piramal Pharma Limited; Peter DeYoung, CEO, Piramal Pharma Solutions.
Preview
Source: PRNewswire
External view, Piramal Pharma Solutions Grangemouth, Scotland Site Expansion.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.